Gonorrhea – Heiki http://heiki.org/ Tue, 24 May 2022 20:57:32 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://heiki.org/wp-content/uploads/2021/04/cropped-icon-32x32.png Gonorrhea – Heiki http://heiki.org/ 32 32 EMA issues final guidance on antibacterial drug development https://heiki.org/ema-issues-final-guidance-on-antibacterial-drug-development/ Tue, 24 May 2022 20:57:32 +0000 https://heiki.org/ema-issues-final-guidance-on-antibacterial-drug-development/

Posted May 24, 2022 | By Joanne S. Eglovitch

The European Medicines Agency (EMA) has published final guidance on the evaluation of antibacterial medicines which is broadly aligned with guidance from other regulators.

The EMA said the paper responds to a “pressing need for new antibacterial agents suitable for the treatment of infections in patients with few remaining therapeutic options”.

The agency announced that antimicrobial resistance poses a “global threat” and is responsible for around 33,000 deaths per year with a cost of 1.5 billion euros per year in health care costs and loss of life. productivity.

The publication of the revised guidance follows a public consultation held in 2016 and reflects the results of discussions between regulators in the EU, US and Japan to align their respective data requirements for antibacterial medicines in order to accelerating the development of these drugs around the world.

The guidelines will come into effect on December 1, 2022. They replace an earlier guideline from 2012. The addendum on the evaluation of medicinal products to treat bacterial infections in children has been revised alongside the guidelines. (RELATED: EMA consults on harmonized guidelines for antibacterial drug development, Regulatory guidance January 14, 2019).

The guidelines contain revised recommendations for primary endpoints, primary analysis population, and non-inferiority margins in trials to support certain site-of-infection indications for use. The revision also provides clarification on clinical programs that aim to address an unmet need and includes new guidelines for treating uncomplicated urinary tract infections and uncomplicated gonorrhea.

The update also removes a section on pharmacokinetic and pharmacodynamic development of antibacterials, as these topics are already covered in separate guidelines.

The document applies to antibacterial agents developed as single agents, antibacterial agents developed for use in combination with one or more other specific antibacterial agents, and beta-lactam (BL) agents developed for use with inhibitors of beta-lactamase (BLI).

The EMA said some of the principles covered in the guidance also apply to agents in development that affect bacterial virulence, bacteriophages proposed to treat infections, agents that inhibit bacterial growth and replicate indirectly, and monoclonal antibodies. used as prophylaxis for specific indications.

The guidelines relate to microbiological investigations; general considerations for clinical programs, such as patient selection, clinical evidence of infection at enrollment, and microbiological evidence of infection at enrollment. It also covers sample collection and dosing schedules.

Other topics include when to switch patients from parenteral therapy to oral therapy and how to test antibacterial agents with licensed agents.

Addendum address development antibacterial children

The EMA has also published an addendum dealing with clinical development programs to support medicines intended to treat bacterial infections in children. The guidance, published on May 20, replaces a preliminary version published in April 2018.

The EMA announced that “for the treatment of certain infections, efficacy results can be extrapolated in certain age groups by examining efficacy data in adults. The addendum mentions that companies developing new antibiotics must develop an extrapolation concept and provide agreement on this in an extrapolation plan.

EMA guideline on antimicrobials

EMA Addendum on Development of Pediatric Antibacterials

© 2022 Society of Regulatory Affairs Professionals.


]]>
Israel and Switzerland file lawsuits, Spain approves anti-epidemic rules https://heiki.org/israel-and-switzerland-file-lawsuits-spain-approves-anti-epidemic-rules/ Sun, 22 May 2022 18:38:58 +0000 https://heiki.org/israel-and-switzerland-file-lawsuits-spain-approves-anti-epidemic-rules/

In the United States, New York authorities announced that a New York resident had tested positive for monkey box virus, was in isolation at home and was awaiting a second confirmation from the Centers for Disease Control.

The New York lawsuit came after Massachusetts health officials first confirmed simian flu on May 18.

US President Joe Biden spoke on the subject for the first time on the sidelines of his Asian tour today, announcing that the impact of spreading bigotry would be “significant”.

Biden said he had not yet been fully briefed by US health officials on America’s “level of exposure” to the virus, but felt “it’s something everyone should be concerned about” because “if it spreads, the impact would be substantial”.

Israeli officials say they have detected the first case of measles in a man returning from a Western European country and are investigating other suspected cases.

Israel’s Health Ministry said the man was admitted to a Tel Aviv hospital on Saturday with mild symptoms, and urged anyone returning from abroad with the flu and skin lesions to seek medical attention.

He specified that the first case of measles in Switzerland had been diagnosed in a man and that the victim was isolated at home following an outpatient consultation.

The man lives in the province of Bern, but was infected with the virus abroad, the provincial health directorate of Bern said on Friday, which published suspicions and laboratory tests confirmed the suspicions on Saturday after -noon.

Contact officials said in a statement that contact tracing had been carried out to identify potential chains of transmission and that all contacts had been notified.

In Spain, the Ministry of Health and the community agreed on Saturday on the protocol to be followed for victims of monkeypox (Monkeypox).

In Spain, there are already at least 30 cases confirmed by PCR test, all linked to the Madrid community and city sauna, which has since been closed, while suspected cases are on the rise across the country, centered in the capital. , Madrid, where there are 15 to 39 suspected cases.

Besides the Madrid community, six other Spanish regions are monitoring potential cases.

The World Health Organization has confirmed that around 80 cases and around 50 suspected cases worldwide are affected by the simian flu.

The disease has been diagnosed in at least 12 countries in the past ten days, including Portugal (23 cases according to the Directorate General of Health), Spain, France, Germany, Great Britain, the United States , Sweden and now Israel and Switzerland.

Smallpox is a rare disease whose pathogen is transmitted from animals to humans and vice versa.

Its symptoms are minimal, similar to those observed in the past in adults: fever, headache, muscle pain, back pain, in the first five days. Then psoriasis, ulcers, blisters and finally scab.

There is no cure for gonorrhea, which usually heals on its own and its symptoms last 14 to 21 days.

]]>
Erie County Health Department Reports Increase in Sexually Transmitted Infections https://heiki.org/erie-county-health-department-reports-increase-in-sexually-transmitted-infections/ Thu, 19 May 2022 22:34:00 +0000 https://heiki.org/erie-county-health-department-reports-increase-in-sexually-transmitted-infections/

BUFFALO, NY (WKBW – The Erie County Department of Health (ECDOH) announced that it has seen an increase in sexually transmitted infections (STIs) in the county and reminds residents that STIs are treatable.

ECDOH said gonorrhea cases increased 56% from 2019 to 2020, although reported chlamydia cases fell 9% from 2019 to 2020. According to ECDOH, chlamydia has fewer symptoms than gonorrhea, which may represent fewer people tested. With 24% of all chlamydia cases and 32% of all gonorrhea cases, ZIP Codes 14215 and 14211 had the highest total number of gonorrhea and chlamydia cases reported in 2021.

According to the ECDOH, confirmed cases of syphilis (all stages) doubled in Erie County from 2020 to 2021. Cases were primarily male (78%), ages 20-39 (67%), and resided in the city of Buffalo (78%). %).

In response, ECDOH is providing information on STI testing and treatment and expanding its Every Partner Treated (EPT) programme. ECDOH said the EPT program provides prescription treatment to partners of people who have been diagnosed with an STI without having to be seen by a medical professional.

“Sexual health is an important part of overall health, and our department’s sexual health clinic is here to support that aspect of personal health. Often the sexual partners of people infected with STIs are also infected and do not know it because they have no symptoms. Treating the partners of people infected with STIs will improve the health of the partners and prevent re-infection of the person who has just been treated. To expand access to this treatment, we have created a new phone line – (716) 858-4EPT. This number and the associated website (www.erie.gov/EPT) are specifically for people who have been exposed to an STI. After being screened by one of our public health nurses, they can receive prompt, free treatment, either by mail or by pick-up at our clinic at 608 William Street. Treatment for all partners is an important way to reduce the risk of reinfection.”

– Health Commissioner Dr Gale Burstein

The ECDOH said the Erie County Sexual Health Clinic at 608 William Street offers testing, treatment and education. The clinic is open on weekdays and is accessible to anyone aged 12 and over. STI testing is confidential and no one is denied testing or treatment because of their ability to pay. Call (716) 858-7687 for more information or call (716) 858-4EPT to access the EPT.

]]>
HHS Advisor Seeking Physician’s Opinion on NSA’s Good Faith Estimate Requirements https://heiki.org/hhs-advisor-seeking-physicians-opinion-on-nsas-good-faith-estimate-requirements/ Tue, 17 May 2022 17:59:37 +0000 https://heiki.org/hhs-advisor-seeking-physicians-opinion-on-nsas-good-faith-estimate-requirements/







May 17, 2022
Hobbies: Advocacy

The Working Group for Electronic Data Interchange (WEDI), an official adviser to the U.S. Department of Health and Human Services (HHS), developed a short survey to assess how well the good faith estimate mandate (GFE) required under the law without surprises is difficult. (NSA) will be for the vendor community. We encourage you to have your say by completing the survey by Friday, May 20.

Effective January 1, 2022, the NSA includes an element of provider transparency for patients considering or planning care. NSA requires providers, including physicians and facilities, to inform patients of their right to receive a good faith estimate and provide a GFE of the expected charges for the services to be provided. At present, GFEs must only be provided to uninsured/self-paid patients – although providers may be required to generate them for patients with health insurance as well. (A self-paid patient refers to someone who has coverage, but chooses not to use its benefits.)

Providers and facilities are required to verbally and in writing inform uninsured/paying patients of their right to GFE. The notice must be prominently posted on the provider’s/facility’s website and in the provider’s office and facility.

In addition to notification, all providers and facilities are also required to provide GFEs to uninsured/paying patients who schedule items or services or request a quote. The GFE should be provided on request or at the time of scheduling, and it should include all services that should be provided to the patient, including by all co-providers, at the initial visit. The provider is required to provide the GFE directly to the uninsured/paying patient. Regulators will exercise their enforcement discretion in requiring GFE for uninsured/self-paid patients until rulemaking to implement this requirement is adopted and enforceable.

The WEDI NSA Task Force is very concerned about the actual application of these requirements and intends to build on the results of the investigation in a letter to the Secretary of HHS. To provide feedback on the GFE requirements, please respond to WEDI’s survey by Friday, May 20.

To return to

]]> CMA President issues statement in response to Governor Newsom’s May budget proposal https://heiki.org/cma-president-issues-statement-in-response-to-governor-newsoms-may-budget-proposal/ Sat, 14 May 2022 00:12:55 +0000 https://heiki.org/cma-president-issues-statement-in-response-to-governor-newsoms-may-budget-proposal/







May 13, 2022

California Medical Association (CMA) President Robert E. Wailes, MD, issued the following statement in response to Governor Gavin Newsom’s May budget review:

“On behalf of the nearly 50,000 physicians, residents and medical students who are members of the California Medical Association (CMA), we are encouraged that Governor Newsom’s budget review puts health care first and demonstrates a commitment continues to provide universal health care access and coverage for all Californians.

The CMA is pleased that the Governor’s proposal recognizes the sacrifices made by our healthcare personnel during the pandemic. As we enter the third year of the pandemic and our healthcare workers continue to deal with the unprecedented crisis, we applaud the Governor’s plan to provide payouts to retain our frontline healthcare workers and to increase funding for vaccinations that will protect patients and keep our communities safe and healthy.

Governor’s Proposed Budget Includes Significant Investments to Reduce Disparities in the Health System and Improve Access and Quality of Care for Children’s Preventative Health, Maternity Care, Women’s Reproductive Health and Integrated Services behavioral health.

In addition, the budget provides critical funding to help small medical practices and safety nets comply with statewide health information exchange requirements that will streamline patient data across 58 California counties.

Our state is blessed with the resources to support those who struggle the most among us, and CMA will continue to advocate for the 13.5 million Californians who depend on essential Medi-Cal programs for their health care.

The CMA looks forward to working with the Legislative Assembly and the Governor to strengthen our health care system, because every Californian deserves access to the highest quality health care.

To return to

]]> Long Lost US Air Force Film Tells Us ‘Where Are The Girls’ https://heiki.org/long-lost-us-air-force-film-tells-us-where-are-the-girls/ Fri, 13 May 2022 13:00:00 +0000 https://heiki.org/long-lost-us-air-force-film-tells-us-where-are-the-girls/

Where are the girls

Image: US Air Force screenshot.

The Airmen are just trying to play pool, but Ernie King is too excited to let them enjoy their game. “You don’t have anything better to do, I’m serious. I think so, he told his sergeant. “Here we are in sultry Southeast Asia. Land of… scented baths. And you guys are standing around the pool table. King finishes berating his fellow airmen before retreating to a brothel. Later it will burn when he pees.

We are in 1969 and the scene takes place in Vietnam. it’s from the movie Where are the girls, a long-lost military instructional video produced by the US Air Force in an effort to prevent Airmen from returning home with sexually transmitted diseases. The motherboard requested a copy from the military, who tracked it down and posted it on the National Archives website. Now anyone can see this classic piece of Cold War venereal disease propaganda, joining the select few who did it of their own free will.

Where are the girls is deeply racist and sexist, which is not shocking for the time, and also highlights an ongoing problem in the US military: the Pentagon has no idea how to talk about sex to soldiers, sailors, airmen and astronauts.

The plot of the film is quite simple. Pete Collins is a young airman serving in Vietnam. He is constantly plagued by the horny aviator King, who enjoys going to brothels, talking about brothels, and pressuring everyone around him to visit them with him. King also proudly never wears a condom.

“Do you take a bath with your shoes on?” he explains. Eventually, he exhausts Collins and the two spend a debauched night on the town where, of course, they both catch STIs: gonorrhea, specifically. Collins is mortified, but King is on his third shot and isn’t worried.

Later, King develops scar tissue in his urethra. “After we got out that time…you having trouble trying to get away?” he asks Collins. “Like when you go, that, uh, doesn’t come out so well.”

It’s a farcical fate, but the worst is in store for the valiant Collins. After a family tragedy sends him home, he decides to marry his waterfront girlfriend. The two go to their doctors for blood tests (a formal requirement for marriage in some states), after which it is revealed that Collins picked up something from her one night of forbidden fun in Vietnam. “A spyrokeet, young man. You have syphilis,” the doctor says as bells ring in the background, evoking the American conception of Vietnamese music.

Worse, explains the doctor, he may have given it to his future wife. The film ends on Collin’s girlfriend’s frozen face as he explains to her that he can’t get married because he kicked her.

Where are the girls try to teach by example. King and Collins’ morality story is meant to speak for itself, and there are two moments of explicit advice given by men in positions of authority. “You are now in a strange country with strange and adorable girls…and even stranger illnesses,” an officer tells a crowd of airmen. “Venereal diseases, for example. You can retrieve them easily here. It doesn’t take long and there are five different types.

The second comes when King and Collins visit the doctor after the night at the brothel. The doc tells them both to stop fucking so much, but if they can’t help it, he insists, they should use condoms. The message comes from stern faces who obviously don’t want to have this conversation.

The US military has long tried to avoid the issue of sex, and the consequences have been devastating. It’s something people called as early as 1955. In pulp magazine War cryan author denounced the state of military sex training videos and blamed “the American attitude towards sex – a guilt and a sense of shame, perhaps – which even prevents adult military strategists from face the realities of life without fear or trembling.”

Things haven’t improved. The Air Force still produces sexual health videos, but they often feel surrealist Tim and Eric sketch. Meanwhile, the US military is no longer an all-male force and integration is not going well. A series of scandals in all branches, from tail hook for Fat Leonardshowed that the U.S. military still doesn’t know how to talk to its servicemen about sex.

Sexual assault is a epidemic in services and victims, men and women, struggle to navigate the Pentagon bureaucracy for any recognition, let alone justice. This month, Task and Purpose published a explosive expose about Marine Corps instructors sexually harassing and mocking people during formal training.

Where are the girls is a holdover from a bygone era, but it is instructive about American military culture. In the first moments of the educational film, the camera pans over Southeast Asian women walking the streets, going about their business. A cartoon rolls along with the title credits, showing a racist stereotype in skimpy clothing.

The implicit message here is clear. American servicemen serving overseas are innocent people, beset by temptation on all sides; the Other covets American money and American manhood, and offers nothing but disease. It dehumanizes everyone involved, which is perhaps useful if you want to train people to kill on command and less so if you want to teach them something useful about the many other demands of military life and life in general. It’s a message that resonates in the US military to this day.

]]>
Cue Health Reports First Quarter 2022 Results https://heiki.org/cue-health-reports-first-quarter-2022-results/ Wed, 11 May 2022 20:01:00 +0000 https://heiki.org/cue-health-reports-first-quarter-2022-results/

SAN DIEGO–(BUSINESS WIRE)–Cue Health Inc. (Nasdaq: HLTH), a health technology company (“Cue”), today released its financial results for the first quarter of 2022.

Recent Highlights

  • Revenues of $179.4 million in the first quarter of 2022, compared to $64.5 million in the first quarter of 2021

  • Over 235,000 Cue Readers shipped through the end of Q1 2022, including over 72,000 during the quarter

  • Covid-19 testing de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance for home and point-of-care use

  • Influenza clinical studies nearing completion, with full FDA submission expected in Q3 2022

  • Influenza + COVID multiplex starts clinical studies this quarter, ahead of schedule

  • RSV is expected to begin clinical studies in the third quarter of 2022 and the Chlamydia + gonorrhea multiplex in the second half of 2022, as planned

  • Cash generated of $16.6 million in the first quarter of 2022, ending with cash and cash equivalents of $426.5 million

“I am pleased with our first quarter 2022 financial results, including $179 million in revenue, reflecting 178% year-over-year growth. We have made excellent progress in our menu expansion activities, with all of our programs on track or ahead of schedule,” said Ayub Khattak, co-founder, president and CEO of Cue Health. “Our recent COVID-19 test de novo The FDA submission marked an important milestone for the company and we believe this will be the first of many submissions as we seek to address a range of diseases and conditions with our menu of molecular diagnostic tests and future offerings. of care.

First quarter 2022 financial results

Revenue was $179.4 million in the first quarter of 2022, an increase from $64.5 million in the first quarter of 2021. The growth was primarily driven by the continued expansion of our customer base and the increase in production capacity.

Private sector revenue increased to 98.0%, or $175.8 million, in the first quarter of 2022.

Public sector revenue was 2.0%, or $3.6 million, in the first quarter of 2022, as we completed delivery of our contract with the U.S. Department of Defense in the fourth quarter of 2021.

Disposable test cartridge revenue was $163.2 million in the first quarter of 2022.

Product gross margin was 51.1% in the first quarter of 2022, compared to 53.4% ​​in the first quarter of 2021.

Operating expenses in the first quarter of 2022 were $89.9 million, excluding cost of revenues, compared to $19.7 million in the first quarter of 2021. The increase was due to the growth of our overall organization, digital marketing expenses and product development expenses.

Net income was $2.8 million in the first quarter of 2022, compared to $13.0 million in the first quarter of 2021. Diluted earnings per share were $0.02 in the first quarter of 2022, compared to 0 $.08 in the first quarter of 2021.

Cash and cash equivalents were $426.5 million as of March 31, 2022.

Orientation

Cue Health expects second-quarter 2022 revenue to be between $50 million and $55 million.

About Cue Health

Cue Health (Nasdaq: HLTH) is a health technology company that makes it easier for people to access health information and places diagnostic information at the center of care. Cue Health empowers people to manage their health with real-time, actionable, and connected health information, giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime , in a device that fits in the palm of your hand. Cue Health’s first COVID-19 test was the first molecular diagnostic test cleared by the FDA for home and over-the-counter use without a prescription or medical supervision. Outside the United States, Cue Health has received CE Marking in the European Union, Interim Prescription Clearance from Health Canada, Regulatory Approval from the Central Drugs Standard Control Organization of India, and Clearance PSAR from the Health Sciences Authority of Singapore. Cue Health was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

Forward-looking statements

The statements in this press release about future expectations, plans and prospects, including statements relating to the submission of any application to the FDA and expectations regarding obtaining clearance, the growth of our customers, expectations regarding production capacity, potential technological improvements and future performance and our guidance, including the first quarter 2022 guidance, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, but not limited to, “continue”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “would”, “develop “, “open”, “seek”, “offer”, “grow”, “expand” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words or words similar. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including those related to the expected capabilities of the new Omicron-specific Cue genotyping test, our ability to maintain customer growth rates, our ability to increase private sector revenue, our ability to maintain or replace revenue historically generated by our government contracts, our ability to effectively scale our manufacturing capacity to meet contractual obligations with our customers and market demand, and the factors discussed in the “Risk Factors” section of Cue’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 is required to be filed with the SEC. All forward-looking statements contained in this press release are based on the current expectations of Cue’s management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This product has not been cleared or approved by the FDA; but has been cleared by the FDA under an Emergency Use Authorization, or EUA. This product has been licensed for the detection of SARS-CoV-2 nucleic acid only, and not for other viruses or pathogens. Emergency use of this product is authorized only for the duration of the declaration of the existence of circumstances justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID -19 under section 564(b)(1) of the Federal Act. Food, Drug and Cosmetic Act, 21 USC § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

CONDENSED INCOME STATEMENTS

(In thousands, except shared data)

Three months completed

March, 31st,

2022

2021

Revenue

Product revenue

$

177,454

$

64,499

Grant and other income

1,956

Total revenue

179,410

64,499

Operating costs and expenses:

Product revenue cost

86,697

30,035

Sales and Marketing

34,168

430

Research and development

28,787

7,409

general and administrative

26,910

11,870

Total operating costs and expenses

176,562

49,744

Operating income (loss)

2,848

14,755

Interest expense

(51

)

(535

)

Other income (expenses), net

6

37

Net profit (loss) before income taxes

2,803

14,257

Income tax expense (benefit)

1,226

Net profit (loss)

$

2,803

$

13,031

Net earnings (loss) per share attributable to common shareholders – basic

$

0.02

$

0.09

Weighted average number of shares used in the calculation of net earnings (loss) per share attributable to common shareholders – basic

146,526,370

18,378,777

Net earnings (loss) per share attributable to common shareholders – diluted

$

0.02

$

0.08

Weighted average number of shares used in the calculation of net earnings per share attributable to ordinary shareholders – diluted

153 036 804

25,904,338

CONDENSED BALANCE SHEET

(In thousands, except share amounts and share data)

March, 31st,

2022

The 31st of December,

2021

Assets

Current assets:

Cash and cash equivalents

$

426 465

$

409,873

Restricted cash

13,838

13,837

Accounts Receivable

75,830

104,589

Inventory

132,567

88,388

Prepaid expenses

42,902

45,889

Other current assets

9,807

7,446

Total current assets

701 409

670,022

Property and equipment, net

182,750

177,456

Rent paid in advance

480

1,567

Operating lease right-of-use assets

84 212

79,474

Intangible assets, net

9,240

7,673

Other non-current assets

5,679

3,868

Total assets

$

983 770

$

940,060

Liabilities, redeemable convertible preferred shares and equity (deficit)

Current liabilities:

Accounts payable

$

48,842

$

37 208

Accrued expenses and other current liabilities

39,809

29,498

Taxes payable on income

8,246

8,297

Deferred income, current

84,629

82 165

Operating lease debts, current

7,594

7,147

Finance lease debts, outstanding

2,620

2,621

Total current liabilities

191,740

166,936

Deferred revenue, net of current portion

10,283

10,283

Liabilities related to operating leases, net of the current portion

47,626

46,464

Finance lease liabilities, net of current portion

2,627

3,271

Other non-current liabilities

6,356

6,356

Total responsibilities

258,632

233 310

Commitments and contingencies (Note 16)

Equity (deficit)

Common shares, par value $0.00001; 500,000,000 and 500,000,000 shares authorized, 146,958,296 and 146,402,991 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively

1

1

Premium

746,352

730 767

Accumulated deficit

(21,215

)

(24,018

)

Total equity (deficit)

725 138

706 750

Total Liabilities, Redeemable Convertible Preferred Shares and Equity (Deficit)

$

983 770

$

940,060

]]> Gonorrhea Diagnostics Market Global Industry Research Analysis and Forecast 2022 to 2027 https://heiki.org/gonorrhea-diagnostics-market-global-industry-research-analysis-and-forecast-2022-to-2027/ Mon, 09 May 2022 20:07:05 +0000 https://heiki.org/gonorrhea-diagnostics-market-global-industry-research-analysis-and-forecast-2022-to-2027/

Global “gonorrhea diagnostics market“The 2022 Reports provide key industry studies for Gonorrhea Diagnostics manufacturers with specific statistics, meaning, definition, SWOT analysis, expert opinion and latest development worldwide. The research report also covers market size, price, sales, revenue, market share, gross margin, growth rate and cost structure. The report aims to provide a further selection of the latest scenario, the economic downturn and the effect of Covid-19 on the industry in general.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://reportsglobe.com/download-sample/?rid=347029

The authors of the report draw up an encyclopedic assessment of the most important regional markets and their evolution in recent years. Readers are provided with accurate facts and figures about the Gonorrhea Diagnostics market and its important factors such as consumption, production, revenue growth, and CAGR. The report also shares gross margin, market share, attractiveness index, and value and volume growth for all segments studied by analysts. It highlights key developments, product portfolio, markets served and other areas depicting business growth of major companies profiled in the report.

The report has been prepared using the latest primary and secondary research methods and tools. Our analysts rely on government documents, white papers, press releases, reliable investor information, financial and quarterly reports, and public and private interviews to gather data and information about the market in which they operate.

Gonorrhea Diagnostics Market Segmentation:

Gonorrhea Diagnostics Market, By Application (2016-2027)

  • Hospital
  • Personal use
  • To research

Gonorrhea Diagnostics Market, By Product (2016-2027)

  • Flow cytometry
  • Diagnostic Imaging
  • Micro droplets of gel
  • Artificial intelligence
  • Chromatography
  • Differential Light Scattering (DLS)
  • Liposomes
  • Monoclonal antibodies
  • Molecular diagnostic tests

Key Players Operating in the Gonorrhea Diagnostics Market:

  • Abbott
  • rock
  • Toso
  • Siemens
  • bioMerieux
  • Perkin Elmer
  • Orthoclinic diagnosis

Get | Discount on the purchase of this report @ https://reportsglobe.com/ask-for-discount/?rid=347029

Scope of the Gonorrhea Diagnostics Market Report

ATTRIBUTES

The description

ESTIMATED YEAR

2022

YEAR OF REFERENCE

2021

FORECAST YEAR

2022 to 2028

HISTORICAL YEAR

2020

SECTORS COVERED

Types, applications, end users, and more.

REPORT COVER

Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends

BY REGION

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

Geographic segment covered in the report:

The Gonorrhea Diagnostics report provides information on the market area, which is divided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate for each region, country and sub-region over the estimated period.

  • North America includes the United States, Canada and Mexico
  • Europe includes Germany, France, UK, Italy, Spain
  • South America includes Colombia, Argentina, Nigeria and Chile
  • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Gonorrhea Diagnostics Market Research Goals and Objectives

  • To understand the Gonorrhea Diagnostics opportunities and advancements determines the market strengths, along with the key regions and countries involved in the market growth.
  • Study the various segments of the Gonorrhea Diagnostics market and the dynamics of Gonorrhea Diagnostics in the market.
  • Categorize the Gonorrhea Diagnostics segments with increasing growth potential and assess the market for the futuristic segment.
  • To analyze the most important trends related to the various segments which help decipher and convince the Gonorrhea Diagnostics market.
  • Check region-specific growth and development in the Gonorrhea Diagnostics Market.
  • Understand the key stakeholders in the Gonorrhea Diagnostics market and the competitive image value of the Gonorrhea Diagnostics market leaders.
  • To study the key plans, initiatives, and strategies for the development of the Gonorrhea Diagnostics Market.

The study thoroughly examines the profiles of major market players and their key financial aspects. This comprehensive business analysis report is useful for all new and existing participants when designing their business strategies. This report covers KEYWORD production, revenue, market share and growth rate for each key company and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Gonorrhea Historical diagnostic distribution data from 2016 to 2021 and forecast for 2022-2028.

Ask questions about personalization at @ https://reportsglobe.com/need-customization/?rid=347029

Some highlights from the table of contents:

1 Presentation of the report

2 Market Trends and Competitive Landscape

3 Gonorrhea Diagnostics Market Segmentation by Types

4 Gonorrhea Diagnostics Market Segmentation by End Users

5 Market Analysis by Major Regions

6 Major Countries Gonorrhea Diagnostics Market Products

7 North America Gonorrhea Diagnostic Landscape Analysis

8 Europe Gonorrhea Diagnostic Landscape Analysis

9 Asia-Pacific Gonorrhea Diagnostic Landscape Analysis

10 Latin America, Middle East and Africa Gonorrhea Diagnostics Landscape Analysis

11 Profile of Key Players

How Reports Globe is different from other market research providers:

The creation of Reports Globe has been underpinned by providing clients with a holistic view of market conditions and future possibilities/opportunities to derive maximum benefit from their business and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and provide the best possible solutions to meet your research needs.

Our team at Reports Globe follows a rigorous data validation process, which allows us to publish publisher reports with minimal or no deviation. Reports Globe collects, separates and publishes over 500 reports each year covering products and services in many areas.

Contact us:

Mr. Mark Williams

Account Manager

WE: +1-970-672-0390

E-mail: [email protected]

Website: Reportsglobe.com

]]>
Increase in STDs in Israel causing serious health problems https://heiki.org/increase-in-stds-in-israel-causing-serious-health-problems/ Sun, 08 May 2022 09:41:05 +0000 https://heiki.org/increase-in-stds-in-israel-causing-serious-health-problems/

A growing number of Israelis are suffering from complications from sexually transmitted diseases like chlamydia, gonorrhea and syphilis, ynet reported.

Over the past two years, sexually transmitted diseases have increased in the country, and it worries experts who fear that bacteria linked to STDs are developing into antibiotic resistance.

“Out of thousands of sexually transmitted disease cases a month, we see dozens of people suffering complications,” said Dr. David Shasha, infectious disease expert and director of the newly opened STD Clinic at Ichilov Medical Center in Tel Aviv. . ynet.

He added that it was a “phenomenon” affecting the whole country.

“Some of the cases are severe and include neurological complications resulting from syphilis or herpes, which sometimes end in disability and brain damage,” he said.

Chlamydia is the most common sexually transmitted disease in Israel, with a 12% increase in recent years. Among other things, it can cause pelvic pain, inflammation, bleeding and pain during intercourse, ynet reported.

In addition, gonorrhea is on the increase and can infect the genitals and throat. It can cause different types of pain, including bleeding during sex or between periods, but 30-60% of women who suffer from it have no symptoms.

Syphilis can develop in different stages, but in the worst case it can damage different organs, including the nervous system, heart, blood vessels and brain.

Video poster

]]>
Evofem presents data detailing fewer urinary tract infections in women using Phexxi in the AMPOWER Phase 3 clinical trial https://heiki.org/evofem-presents-data-detailing-fewer-urinary-tract-infections-in-women-using-phexxi-in-the-ampower-phase-3-clinical-trial/ Fri, 06 May 2022 13:17:00 +0000 https://heiki.org/evofem-presents-data-detailing-fewer-urinary-tract-infections-in-women-using-phexxi-in-the-ampower-phase-3-clinical-trial/

  • 5.8% of women in the AMPOWER trial experienced a urinary tract infection during the study, compared to 11% in the general population
  • the post hoc The analysis will be presented at the 2022 Annual Meeting of the American College of Obstetricians and Gynecologists (ACOG) in San Diego, California on

    May 7, 2022


SAN DIEGO, May 6, 2022 /PRNewswire/ — Evofem Biosciences Inc., (Nasdaq: EVFM) today announced that new data from the AMPOWER Phase 3 clinical trial of Phexxi® (lactic acid, citric acid and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) than the general population.



dr. Bassem Maximethe senior poster author will present this new dataset at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting on Saturday, May 7, 2022. Details of the presentation and data can be found here: ACOG 2022 Annual Clinical and Scientific Meeting: Meeting Details (pathable.com).


“In this post hoc women who used Phexxi had significantly fewer UTIs compared to the general population,” said Dr. Bassem Maximelead author of the study and director of Maximos Ob/Gyn in League City, Texas. “These data provide information worthy of further investigation to determine whether Phexxi has an impact on UTIs in women.”


AMPOWER was a single-arm, multicenter, Phase 3 study evaluating the efficacy and safety of Phexxi for the prevention of pregnancy.


Of the 1,339 women who self-administered at least one dose of Phexxi and entered the safety population, 77 (5.8%) experienced a UTI during the study. Of the 77 women who experienced UTIs, one woman experienced an event classified as “bacterial urinary tract infection”; the remaining 76 women had events classified as “urinary tract infection”. Adverse events (≥2%; N=1330) were consistent with the results of the overall study findings.


“The Phase 3 AMPOWER study continues to provide data showing a greater and positive impact on a woman’s sexual, reproductive and general health,” said Saundra Pelletier, Managing Director, Evofem. “Later this year, we will read key data from our EVOGUARD Phase 3 registration trial of Phexxi for the prevention of chlamydia and gonorrhea, which, if approved, could further expand the opportunities for Phexxi. to protect women’s health.


About Phexxi
Phexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex.


Important Safety Information


  • Rare cases (0.36%) of bladder and kidney infections have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.
  • Contact your health care provider if you experience genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.
  • Phexxi does not protect against sexually transmitted infections, including HIV.


For more information about Phexxi, talk to your healthcare provider and see complete product information at www.phexxi.com.


Please report side effects by contacting Evofem Biosciences toll-free at 1-833-EVFMBIO or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Intended for US residents only.


About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) develops and markets innovative products to address the unmet sexual and reproductive health needs of women, including hormone-free, female-controlled contraception and protection against chlamydia and gonorrhea. The company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a prescription vaginal contraceptive gel without hormones. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each sexual intercourse. Learn more at phexxi.com and evofem.com.


Phexxi® is a registered trademark of Evofem Biosciences, Inc.


Forward-looking statements
This press release contains “forward-looking statements”, within the meaning of the safe harbor for forward-looking statements provided for by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including , without limitation, statements regarding timing and outcome of Phase 3 registration EVOGUARD trial and any submission or approval of Phexxi to or by the FDA for the prevention of chlamydia and gonorrhea. A variety of factors could cause actual results to differ materially from those discussed or implied by the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on such forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could adversely affect the value of the assets and businesses of Evofem Biosciences, are disclosed in the documents filed by the Company with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 10, 2022. All forward-looking statements are expressly qualified in their entirety by these factors . The Company undertakes no obligation to update forward-looking statements, except as required by law.


Media Contact

jack hirschfield
Evofem Biosciences, Inc.
jhirschfield@evofem.com
(512) 674-5163


Investor Relations

Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775




Quote See original content to download multimedia: https://www.prnewswire.com/news-releases/evofem-presents-data-detailing-fewer-urinary-tract-infections-in-women-using-phexxi-in-the -phase-3-ampower-clinical-trial-301541565.html


SOURCEEvofem Biosciences, Inc.

]]>